ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EDIT Editas Medicine Inc

7.86
0.14 (1.81%)
Pre Market
Last Updated: 05:52:16
Delayed by 15 minutes

Period:

Draw Mode:

Volume 305
Bid Price 7.70
Ask Price 7.90
News -
Day High

Low
6.0799

52 Week Range

High
11.91

Day Low
Company Name Stock Ticker Symbol Market Type
Editas Medicine Inc EDIT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.14 1.81% 7.86 05:52:16
Open Price Low Price High Price Close Price Prev Close
7.72
Trades Volume Avg Volume 52 Week Range
8 305 - 6.0799 - 11.91
Last Trade Time Type Quantity Stock Price Currency
05:52:14 formt 163 $ 7.86 USD

Editas Medicine Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
631.6M 81.81M - 78.12M -153.22M -1.87 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Editas Medicine News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No EDIT Message Board. Create One! See More Posts on EDIT Message Board See More Message Board Posts

Historical EDIT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week9.029.087.708.152,682,902-1.16-12.86%
1 Month8.0011.587.629.142,434,567-0.14-1.75%
3 Months10.8811.586.888.751,862,026-3.02-27.76%
6 Months8.0111.696.07998.771,887,271-0.15-1.87%
1 Year8.3711.916.07998.741,859,864-0.51-6.09%
3 Years43.5073.0256.079919.381,752,234-35.64-81.93%
5 Years24.1299.956.079926.031,510,574-16.26-67.41%

Editas Medicine Description

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology.

Your Recent History

Delayed Upgrade Clock